Abramson Cancer Center at Penn Medicine
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Abramson Cancer Center at Penn Medicine sits in the top decile of US sponsors by registered trial count (#92 of 15,742 sponsors by registered trial count).
Abramson Cancer Center at Penn Medicine: 402 sponsored US clinical trials, 74 recruiting.
Abramson Cancer Center at Penn Medicine sponsors 402 registered US clinical trials on ClinicalTrials.gov, 74 of them currently recruiting, and 235 completed. 3 of these trials are in Phase 3-4 (later-stage) and 175 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 20 trials.
Top-decile sponsor footprint
Abramson Cancer Center at Penn Medicine ranks in the top decile of sponsors by registered trial count (#92 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
235 of 280 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
402 total, page 6 of 9
Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)
NCT02233504
FDG-PET/CT Imaging as Early Predictor of DP
NCT02476734
Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts
NCT02246738
Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study
NCT02514499
Assessment of Cancer Concerns at the End of Treatment (ACE)
NCT02514486
Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
NCT02207439
Adherence to Aromatase Inhibitors: The Role of Partners
NCT02753985
Validation of Edema-invariant Multi-shell High Angular Resolution Diffusion Imaging (msHARDI)-Based Tractography With Intra-operative Cortical Stimulation
NCT02559401
Patient-Centered Acupuncture for Pain (PCAP)
NCT02152020
A Pilot Study at a Single-Institution of Pregabalin in the Management of Mucositis Pain in Patients Undergoing Chemoradiation Therapy to the Head and Neck.
NCT02277548
Acupuncture Feasibility Trial for Dyspnea in Lung Cancer
NCT02094950
Functional Outcome Measures for Head and Neck Patients
NCT02530112
[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers
NCT02108457
A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer
NCT02159703
A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
NCT02030860
Ablative Fractional Laser for Sclerotic GVHD-Associated Joint Contractures
NCT02881047
Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients
NCT01994850
Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC
NCT02013778
Suitability of DCE-MRI for Detection of Vascular Changes After VBT
NCT01991808
A Pilot Study to Evaluate Radiotherapy-Induced Anti-Tumor Immunity in Metastatic Carcinoma of the Pancreas
NCT01985958
Surveillance Markers of Utility for Recurrence After Neoadjuvant Chemotherapy for Breast Cancer
NCT02830282
A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
NCT01897116
Study Of Circulating Multiple Myeloma Cells As A Biomarker of MGUS And SMM
NCT01958528
HPV Serum DNA Levels Predicting Outcome in p16+ Squamous Cell Head and Neck Cancer
NCT01984359
APBI Proton Feasibility and Phase II Study
NCT01839838
A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma
NCT01839799
CTCs for High Grade Glioma
NCT02558335
A Feasibility Study Followed By A Randomized Phase II Study Of Yoga For Radiation Therapy Side Effects In Prostate Cancer
NCT02135653
Multiple Myeloma and Exercise
NCT01809717
Yoga for Breast Cancer
NCT01985945
Phase II Maraviroc for GVHD Prevention
NCT01785810
Etirinotecan Pegol (NKTR-102) in NSCLC
NCT01773109
A Study of the Communication of Genetic Test Results By Telephone: A Multi-Center Study
NCT01736345
The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy
NCT02135679
Autophagy Induction After Bortezomib for Myeloma
NCT01594242
Functional MRI Use in Prostate Radiation Treatment Planning
NCT01985932
CRLX101 Plus Bevacizumab in Advanced RCC
NCT01625936
Multi-peptide Vaccine With Basilixumab for Breast Cancer
NCT01660529
Dovitinib in Neuroendocrine Tumors
NCT01635907
Maintenance Lenalidomide in Lymphoma
NCT01575860
Ruxolitinib in Estrogen Receptor Positive Breast Cancer
NCT01594216
Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma
NCT01456585
Proton Radiotherapy for Stage I, IIA, and IIB Seminoma
NCT01557790
Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)
NCT01676831
Does Cryofixation of Skin Specimens Affect Quality of Subsequent Formalin Fixed Paraffin Embedded H and E Histology
NCT01540695
MLN8237 in Head and Neck Cancer
NCT01540682
Peripheral vs. Selective Tumor Marker Venous Sampling in Prostate Cancer
NCT02479945
A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy
NCT01661166
Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer
NCT01520038
A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer
NCT01506973
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 113 |
| Phase 2 | 62 |
| Phase 3 | 1 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the Abramson Cancer Center at Penn Medicine pipeline
74 recruiting of 402 indexed (18% open); 235 completed (58%).
Phase mix: 3 late (III/IV) vs 175 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (20 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Abramson Cancer Center at Penn Medicine: open-pipeline peers nationwide
Peers matched on 402 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
Abramson Cancer Center at Penn Medicine sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 402 trials (± recruiting share)
- Case Comprehensive Cancer Center · 407 trials · 14% recruiting
- University of Nebraska · 407 trials · 13% recruiting
- Takeda · 408 trials · 12% recruiting
- University of Kansas Medical Center · 408 trials · 23% recruiting
Sponsors near 18% open enrollment (± trial volume)
- University of Maryland, Baltimore · 18% recruiting · 560 trials
- Henry Ford Health System · 18% recruiting · 234 trials
- New York Institute of Technology · 18% recruiting · 49 trials
- University of California, San Diego · 18% recruiting · 775 trials
Related
What to do with this Abramson Cancer Center at Penn Medicine page
402 registered trials is a research-attention snapshot, not an endorsement of Abramson Cancer Center at Penn Medicine or any single study.
- 74 of Abramson Cancer Center at Penn Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Abramson Cancer Center at Penn Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Abramson Cancer Center at Penn Medicine pipeline card: 402 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.